Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 22;40:297. doi: 10.1186/s13046-021-02059-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — XMU-MP-2 inhibits the PTK6 induced proliferation, stemness, and chemoresistance of CRC cells. A The in vitro limiting dilution assays show the effects of XMU-MP-2 on the PTK6 enhanced formation of tumor spheres (mean ± SD, n = 12), likelihood ratio test. B CCK-8 assays were performed to determine the effects of XMU-MP-2 on the PTK6 induced proliferation CRC cells (mean ± SD, n = 3). C Colony formation assays were performed to determine the effects of XMU-MP-2 on PTK6 induced growth of CRC cells. The number of colonies (> 50 cells) was scored (mean ± SD, n = 3). D Dose–response curves show the effects of XMU-MP-2 on the sensitivity of vector, PTK6^WTand PTK6^YF overexpression CRC cells to chemotherapy drugs (mean ± SD, n = 3). E The numbers of CD133 + cells in indicated CRC cells were evaluated by flow cytometry (mean ± SD, n = 3). F Immunofluorescence staining of CRC cells shows that XMU-MP-2 can inhibit the phosphorylation of PTK6, as well as the activation of its downstream STAT3 signaling. G Immunofluorescence staining of CRC cells and CSC spheres shows that XMU-MP-2 can inhibit the phosphorylation of PTK6 and the expression of stem cell markers. H Western blot assays indicate that XMU-MP-2 can inhibit the PTK6 induced activation of JAK2/STAT3 signaling and the expression of stem cell markers. *P < 0.05, **P < 0.01, ***P < 0.001